Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Debra Hanna

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Intellectual and Developmental Disabilities|February 5, 2019
An Algorithmic Approach to Nutritional Difficulties in People With Developmental DisabilitiesSuma Chennubhotla, Rebecca Hertog, John E Williams, et al.
Journal of Pharmacokinetics and Pharmacodynamics|March 10, 2018
Quantitative approach for cardiac risk assessment and interpretation in tuberculosis drug developmentSebastian Polak, Klaus Romero, Alexander Berg, et al.
The AAPS Journal|March 16, 2018
Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Assessment Strategy in TdP Risk Assessment of MoxifloxacinNikunjkumar Patel, Oliver Hatley, Alexander Berg, et al.
Antimicrobial Agents and Chemotherapy|December 29, 2025
A stochastic simulation-based approach to inform the relapsing mouse model study design for non-clinical assessment of tuberculosisJames Clary, Jessica K Roberts, Debra Hanna, et al.
The Journal of Antimicrobial Chemotherapy|February 16, 2023
Hollow-fibre system model of tuberculosis reproducibility and performance specifications for best practice in drug and combination therapy developmentTawanda Gumbo, Shashikant Srivastava, Devyani Deshpande, et al.
The Lancet. Infectious Diseases|March 28, 2013
Tuberculosis biomarkers discovery: developments, needs, and challengesRobert S Wallis, Peter Kim, Stewart Cole, et al.
Antimicrobial Agents and Chemotherapy|January 31, 2022
Model-Based Meta-Analysis of Relapsing Mouse Model Studies from the Critical Path to Tuberculosis Drug Regimens Initiative DatabaseAlexander Berg, James Clary, Debra Hanna, et al.
Antimicrobial Agents and Chemotherapy|October 12, 2011
Evaluation of pharmacokinetic/pharmacodynamic relationships of PD-0162819, a biotin carboxylase inhibitor representing a new class of antibacterial compounds, using in vitro infection modelsAdam Ogden, Michael Kuhn, Michael Dority, et al.
The Journal of Antimicrobial Chemotherapy|June 12, 2012
Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutationsBrian T Tsuji, Jurgen B Bulitta, Tanya Brown, et al.
The Journal of Antimicrobial Chemotherapy|November 13, 2019
Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematicsShashikant Srivastava, Devyani Deshpande, Gesham Magombedze, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Intellectual and Developmental Disabilities|February 5, 2019
An Algorithmic Approach to Nutritional Difficulties in People With Developmental DisabilitiesSuma Chennubhotla, Rebecca Hertog, John E Williams, et al.
Journal of Pharmacokinetics and Pharmacodynamics|March 10, 2018
Quantitative approach for cardiac risk assessment and interpretation in tuberculosis drug developmentSebastian Polak, Klaus Romero, Alexander Berg, et al.
The AAPS Journal|March 16, 2018
Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Assessment Strategy in TdP Risk Assessment of MoxifloxacinNikunjkumar Patel, Oliver Hatley, Alexander Berg, et al.
Antimicrobial Agents and Chemotherapy|December 29, 2025
A stochastic simulation-based approach to inform the relapsing mouse model study design for non-clinical assessment of tuberculosisJames Clary, Jessica K Roberts, Debra Hanna, et al.
The Journal of Antimicrobial Chemotherapy|February 16, 2023
Hollow-fibre system model of tuberculosis reproducibility and performance specifications for best practice in drug and combination therapy developmentTawanda Gumbo, Shashikant Srivastava, Devyani Deshpande, et al.
The Lancet. Infectious Diseases|March 28, 2013
Tuberculosis biomarkers discovery: developments, needs, and challengesRobert S Wallis, Peter Kim, Stewart Cole, et al.
Antimicrobial Agents and Chemotherapy|January 31, 2022
Model-Based Meta-Analysis of Relapsing Mouse Model Studies from the Critical Path to Tuberculosis Drug Regimens Initiative DatabaseAlexander Berg, James Clary, Debra Hanna, et al.
Antimicrobial Agents and Chemotherapy|October 12, 2011
Evaluation of pharmacokinetic/pharmacodynamic relationships of PD-0162819, a biotin carboxylase inhibitor representing a new class of antibacterial compounds, using in vitro infection modelsAdam Ogden, Michael Kuhn, Michael Dority, et al.
The Journal of Antimicrobial Chemotherapy|June 12, 2012
Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutationsBrian T Tsuji, Jurgen B Bulitta, Tanya Brown, et al.
The Journal of Antimicrobial Chemotherapy|November 13, 2019
Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematicsShashikant Srivastava, Devyani Deshpande, Gesham Magombedze, et al.
Pageof 4